Updates in Advanced and Recurrent Endometrial Cancer
Kathleen N. Moore, MD, MS
Associate Director of Clinical Research
Stephenson Cancer Center, University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma
Ramez Eskander, MD
University of California, San Diego
La Jolla, California
Joyce Liu, MD, MPH
Associate Chief and Director of Clinical Research, Division of Gynecologic Oncology
Dana-Farber Cancer Institute
Provided by HMP Education, an HMP Global Company.
For questions regarding this educational activity, please call 609-371-1137 or email firstname.lastname@example.org.
These activities are intended for community and academic clinicians who care for patients with breast and gynecologic cancers, including medical oncologists, surgical oncologists, radiation oncologists, OB/GYNs, breast surgeons, NPs/PAs, and other healthcare professionals (eg, oncology nurses, pharmacists, navigators, physicians-in-training).
After participating in this activity, learners should be better able to:
• Describe the implications of evolving EC classification systems for clinical practice
• Evaluate newer and emerging targeted agents and immunotherapies in EC
• Implement strategies for optimal management of adverse events in EC
• Address cultural, ethnic, and racial disparities related to risk factors, diagnosis, and treatment in EC.
To be eligible for credit, participants must complete the online activity and the evaluation. Upon completing the activity, there will be instructions on how to complete the evaluation and print a certificate or other documentation of credit.
Release Date: May 30, 2022
Expiration Date: May 30, 2023
Estimated Time to Complete: 1.00 hour
There is no fee associated with this activity.
In support of improving patient care, HMP Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
HMP Education designates this internet enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This internet enduring, knowledge-based activity (Universal Activity Number: JA0006201-0000-22-051-H01-P) has been approved for a maximum of 1.00 contact hours (0.1 CEUs).
The certificate is not the official record of your participation in the activity. The official record of credit will be the information in the CPE Monitor system. Following ACPE Policy, HMP Education must transmit your claim to CPE Monitor within 60 days from the date you complete this CPE activity. HMP Education is not able to report your claimed credit after this 60-day period. Eligibility for pharmacy credit is contingent upon the successful completion of a post-test and/or evaluation for each activity or session attended.
This continuing nursing education internet enduring activity awards 1.00 contact hours. Provider approved by the California Board of Registered Nursing, Provider #13255 for 1.00 contact hour.
American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 CreditTM from organizations accredited by the ACCME.
HMP Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This internet enduring activity is designated for 1.00 AAPA Category 1 credit(s). PAs should only claim credit commensurate with the extent of their participation.
USE OF PROPRIETARY NAMES
This continuing medical education activity may include device or medicine brand names for participant clarity purposes only, due to the presence of different branded versions of the same product. No product promotion or recommendation should be inferred.
UNAPPROVED AND/OR INVESTIGATIONAL USES OF DRUGS AND DEVICES
This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the European Medicines Agency (EMA) of the European Union or the Food and Drug Administration (FDA) of the United States. Participants are strongly encouraged to consult approved product labeling for any drug or device mentioned in this activity before use. The opinions expressed during this activity are the opinions of the respective authors, presenters or moderators and do not necessarily reflect the opinions of HMP Education.
The material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individual’s own physician.
Neither HMP Education nor any of its subsidiaries or affiliates is affiliated with, or formally endorsed by a medical society.
The opinions expressed in this educational activity are those of the faculty and are not attributable to HMP Education or HMP. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
HMP Education is an independent provider of continuing medical education. HMP Education has no proprietary or financial interest in medical or healthcare products over which the FDA (USA) or EMA (EU) has regulatory authority.
In accordance with our disclosure policies, HMP Education is committed to ensuring balance, independence, objectivity, and scientific rigor for all accredited continuing education. These policies include assigning relevance to, and mitigating, all perceived or real conflicts of interest between any individual with control over the content and any ineligible company (commercial interest) as defined by the ACCME.
Any individual with control over accredited content, including planner, faculty, and reviewer, is required to globally disclose:
- Individual relationship(s) or lack thereof, and its nature, with any/all ineligible company, and;
- Any investigational, off-label, or non-FDA approved content or discussion
HMP Education has reviewed these disclosures, assigned relevance based on the relationship and scope of content, and identified those with the potential to compromise the goals and educational integrity of the education. Relevant relationships, or lack thereof, are shared with the learner.
Education has been independently peer-reviewed to validate content, mitigate identified conflicts of interest, and ensure:
- All recommendations involving clinical medicine is based on evidence that is accepted within the medical profession as adequate justification for their indications and contraindications in the care of patients.
- All scientific research referred to, reported, or used in accredited continuing education in support or justification of a patient care recommendation conforms to the generally accepted standards of experimental design, data collection, and analysis.
- Content is appropriate, fair and balanced, unbiased, referenced, and non-promotional.
The faculty has reported the following:
Kathleen N. Moore: Advisory Board - Alkermes, Aravive, AstraZeneca, Blueprint, Eisai Inc., Elevar, EMD Serono, Genentech, GOG Foundation, GOG Partners, GSK/Tesaro, Henguri, IMab, Immunogen, INXMED, Lilly, Merck, Mereo Therapeutics, Mersana, Myriad, Novartis, OncoNova, OncXerna, Tarveda, VBL Therapeutics, Verastem; Grant/Research Support - GSK/Tersaro, Lilly, Merck, PTC Therapeuticslogy, Silverback Therapeutics, CytomX, Pfizer, Mersana, Black Diamond, H3 Biomedicine, Daiichi Sankyo
Ramez Eskander: Advisory Board - AstraZeneca, Daiichi Sankyo, Eisai, EQRx, Immunogen, Merck, Myriad, Novocure, Seagen; Consultant - AstraZeneca, Eisai, Elevar, Merck, Myriad
Joyce Liu: Advisory Board - AstraZeneca, Eisai, Genentech, GSK, Regeneron; Other Financial or Material Support - Clovis Oncology
EDUCATION PLANNING COMMITTEE
HMP Education planning committee includes Dena Moftah, Samantha Conforti, Randy Robbin, and Andrea Zimmerman.
No HMP Education planner or staff has disclosed a relevant financial relationship with any ineligible company (commercial interest).
HMP Education complies with the legal requirements of the Americans with Disabilities Act and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please call 609-371-1137.
HMP Education protects the privacy of personal and other information regarding participants, educational partners, and joint providers. HMP Education and our joint providers will not release personally identifiable information to a third party without the individual’s consent, except such information as is required for reporting purposes to the appropriate accrediting agency. HMP Education maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.
Copyright © 2022 by HMP Education. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from HMP Education.
Any participant wanting to file a grievance with respect to any aspect of a continuing education activity accredited by HMP Education may contact Samantha Conforti, Senior Manager, Accreditation and Compliance, by phone at 609-371-1137, by email at email@example.com or in writing at 104 Windsor Center Drive, East Windsor, NJ 08520. Ms. Conforti will review the grievance and respond within 30 days of receiving the complaint.
Talks within this session are supported by educational grants provided by Karyopharm Therapeutics.